



Modern Medicine and Pharmaceuticals

Rehan Haider^{1*}, Asghar Mehdi², Anjum Zehra³, Geetha Kumari Das⁴, Zameer Ahmed⁵, Sambreen Zameer⁶

^{1,3}University of Karachi

²Air University Karachi

⁴University Rajasthan

^{5,6}Dow University of Health Sciences Karachi

Corresponding Author: Rehan Haider rehan_haider64@yahoo.com

ARTICLE INFO

Keywords: Personalized Medicine, Genomic Medicine, Immunotherapy

Received : 10 February

Revised : 17 March

Accepted: 18 April

©2024 Haider, Mehdi, Zehra, Das, Ahmed, Zameer: This is an open access article distributed under the terms of the

[Creative Commons Attribution 4.0 International](https://creativecommons.org/licenses/by/4.0/).



ABSTRACT

Modern Medicine and pharmaceuticals have made tremendous strides in enhancing the healthcare and quality of life of people worldwide. This summary explores the key traits and trends in these fields. In recent decades, current medications have witnessed a paradigm shift toward personalized healthcare. Improvements in genomics, proteomics, and record analytics have paved the way for precision medication and tailoring treatments for an individual's genetic makeup. This technique enhances treatment efficacy while minimizing aspect consequences, marking a significant departure from the one-size-fits-all approach. Pharmaceutical research has experienced a revolution with the advent of biotechnology. Biopharmaceuticals, along with monoclonal antibodies and gene treatment plans, have emerged as powerful tools for the fight against formerly untreatable illnesses. Their ability to target specific molecules or genes has opened new frontiers in cancer treatment, uncommon illnesses, and autoimmune diseases. Furthermore, pharmaceutical enterprises have embraced virtual technologies. AI-pushed drug discovery, *in silico* medical trials, and telemedicine reshape the drug development pipeline and improve the care of affected persons. In particular, telemedicine has gained prominence, presenting available healthcare offerings and far-flung tracking. However, these advancements have moral and regulatory demands. Privateness issues, information protection, and equitable access to present-day remedies remain essential issues. The need for strong moral frameworks and regulatory oversight is paramount

INTRODUCTION

There is evidence from early civilizations in Africa, Asia, and Europe that people have used medicinal drugs to treat contamination. Far-reaching remedies that involve Shamanism, Surgical procedures, and drug formulations have been developed. Drugs come from plants worldwide. Animals and minerals that are secondhand for curative functions are called "Crude capsules." As knowledge of illness and medications has increased, apart from the extra-freed form of the essences, they have been picked to make further effective pills and drugs. cause of the development of contemporary organizations worldwide, distinct reflective strategies for curative treatment have received attention. Within the Japanese organization, which is contained In China and India, holistic methods have been used. In these institutions, disease or contamination is thought to be an elemental indiscriminate frame and can be rectified by accompanying the preferred food or system of natural pills, for the most part, plants and any from animals or minerals together, accompanying the frame endorsement. However, in Western organizations, nausea is captured into concern as a separate system from the frame and may be removed next to the surgical operation or the use of exact synthetic elements. Specifically, within Western medicine, the exercise of utilizing freed forms or clean synthetic substances has grown. The talent in synthetic sciences, specifically synthetic allure and cleansing blueprints, has existed and has carefully grown to accomplish the desire for synthetic essences. This led to no more handiest dream for the growth of concerning details of talent and eras, but also the plan of machine control. A pure synthetic entity is not executed immediately on the illness state to a circumstance or treat the ailment. Numerous sets of instructions and management strategies are in use, depending on the nature of the problem and the chemical makeup of the therapeutic components. The greatest way for the medicinal entity's healing effects to be experienced is if the appropriate synthetic chemical is combined with enough load is caused inside the attracted tissue websites for the distance momentary inside the personality-bearing pathophysiological circumstances. Formulations play an important role by spreading tablets inside the corpse. moreover, by the kind and position of the flu, equal drug essence might offer separate curative consequences, generally establishing the types of the system, way, and speech of administrations In modern ways of living, the ending 'drug' represents pharmacologically alive synthetic stuff. Pharmaceutical sciences supply information and methods to utilize the drug stuff for a persuasive cure. In recent years, with the progress in drug science, several drug entities have been promoted for energy benefits. Pharmaceutical industries contributed significantly to the progress of modern cures in addition to the incident of a particular formulation for the asked route of the presidency, so that it obtains the best healing worth of the drug's wealth.

LITERATURE REVIEW

Historical Overview of the Development of Modern Drugs

A large number of pharmaceutical products that are sold as used today have specific factual connections to their typical applications. The history of drugs and acetylsalicylic acid, an anesthetic, is a topic of much debate and documentation among the ruling classes. There is proof that the traditional Chinese, Ayurvedic, and Ancient Greek treatments for pain alleviation included a pigmented covering of the narcotic herb *Papaverum somniferum*. Since human nature sinks in the open ocean, there has always been a need to obtain more potent and pure medicines. Derosne penned the first account of the opiate-freeing in 1803, and Seguin followed suit in 1814. (Seguin, 1814; Derosne, 1803). German druggist Sertürner was written to demand that the live chemical be cleaned of its drug-tinted covering before anything else could be done. in 1805; subsequently, it was determined that the special substance was identified as meconic acid and not a soluble narcotic component (Sertürner, 1805; 1806). Sertürner obtained a clean, glittering compound with narcotic characteristics and elicited the narcotic-tinted covering that accompanied trouble and the speeding liquid that accompanied problem (Sertürner, 1817). The substance was selected as the anesthetic (1), and the dosage became routine subsequently. Wright began dosing (2) in 1874; the drug's diacetyl derivative was sold by Bayer AG in 1898 (Wright, 1874). Opium was banned from being used for medicinal purposes due to its strong narcotic properties, but medicines and narcotic (3), another type of anesthetic derivative, remain the most widely used pharmaceuticals almost 200 years after they were discovered (Figure 1).




Figure 1. Structure of Morphine and it's Derivatives

The technique was utilized to eliminate more primary alkaloids after ancestry and drug-free, and the results were quickly marketed. Pelletier et al. reported in 1817 that Strychnine (5) from *Strychnos* and Emetine (4) from *Ipecacuanha*. Similar claims were made in 1820 by a group that excluded verbal attacks (6) from the *Cincona* class (Pelletier, 1820), which was sold as an antagonistic-malarial medication. Other major alkaloids were private, including atropine (10) in 1848, brucine (7) and hot drinks made from tree beans (8) in 1819, colchicine (9) in 1920, and drugs (3) in 1833 (Nicolaou & Montagnon, 2008). The building, or 826, was completed when its construction was clarified in 1870 and then united in 1881. Given that these medications have almost 200 years of

history, are still considered used in terms of marketing (Figure 2) (Newman, 2010).




Figure 2. Structure of Alkaloids Having Therapeutic and Commercial Uses
Discovery of These

Alkaloids led to the foundation for the modern medicine and industrialization.

Acetylsalicylic acid, an anesthetic, is another novel medication with a lengthy history and hotly contested ingredients (13). Although there are several effective antipyretic medications available, the importance of anesthesia has never been documented. A mild, non-narcotic Leroux-derived anodyne, acetylsalicylic acid (13), is the acetyl derivative of salicylic acid (14). This helps with power, joint aches, and trouble relaxation. The medication stops prostaglandins, which make bare areas more sensitive to pain. Salicylaldehyde (15) and salicin (16), a synthetic component derived from the bark of willow saplings, are related to the discovery of anesthetic (13) in reference 14. Hippocrates, the father of modern medicine (460–377 B.C.), described the use of powdered emerald bark from colorful forests as a remedy for headaches, pains, and fevers. By 1829, scientists had discovered that the component in emerald-colored plants that helped with pain was salicin (16). Johann Buchner kept the live component of emerald in its colorful bark a secret. A small number of tease-like, sharp-judging yellow crystals that he termed salicin. In 1826, salicin was obtained by two Italians, Brugnatelli and Fondant, but it was in a highly blended form. Salicin was originally produced in transparent form by Henri Leroux in 1829. Raffaele Piria conquered this in 1839 by obtaining salicylic acid by decomposition (Piria, 1839) (Figure 3). Salicylic acid is an antipyretic and accompanying pain reliever, however it cannot be professionally pushed for its attractiveness or strong aftereffects of stomach disturbances. The effects of

salicylic acid were countered in 1853 by French researcher Charles Frederic Gerhardt by buffering it with sodium acetyl chloride with sodium salicylate hydroxide.




Figure 3. Structure of Aspirin and Other Related Compounds. Salicin, a Compound Isolated from the Bark of Willow Tree Led to the Discovery of Aspirin

Acetylsalicylic acid conception. It is not possible to market Gerhardt's discoveries (Gerhardt, 1853; Nicolaou and Montagnon, 2008). Gerhardt's recipe was updated in 1899 by Felix Hoffmann, a German researcher who worked with Bayer. Felix Hoffmann made it possible for the welcome father – the one who was in excruciating pain from arthritis – to exist. Bayer demonstrated a new miracle medication with promising outcomes (Nicolaou & Montagnon, 2008). February 27, 1900, was a dominant day for aspirin. The "spirit" for *Spiraea ulmaria*, the source of salicylic acid, was likely 'A' for acetyl, and 'in the ending name for Initially, anesthetics were sold as powders, but advertisements for the first anesthetic tablets appeared in 1915. Bayer's trademarks were aspirin and smack. Following Germany's withdrawal from the war, Bayer strained must give up two trademarks in 1919 as a condition of the Treaty of Versailles (Belis, 2012). Apart from opiates and anesthetics, other synthetic wealth started to control machines and changed our hierarchy due to the rise of allied cultures and the spread of ways to locate modern treatments. Table 1 lists the major medications along with their medicinal applications and the order in which they were discovered.

Table 1. A List of Some Important Modern Medicines in Chronological Order of Discovery with Therapeutic Uses

Year	Drug substance	Therapeutic uses
1806	Morphine	Analgesic, sedative
1875	Salicylic acid	Analgesic, antipyretic
1884	Cocaine	CNS stimulant (serotonin-dopamin-norepinephrine reuptake inhibitor), local anesthetic
1888	Phenacetin	Analgesic, antipyretic
1889	Acetyl salicylic acid	Analgesic, antipyretic (cyclooxygenase inhibitor)
1903	Barbiturate	Sedative
1909	Arsphenamine	Treatment for syphilis and trypanosomiasis
1921	Procain	local anesthetics (sodium channel blocker)
1922	Insulin	Anti-diabetic
1928	Estron	Sex hormone
1928	Penicillin	Anti-biotic
1935	Sulphachrysoidin	Anti-bacterial
1944	Streptomycin	Anti-biotic
1945	Chloroquin	Anti-malarial
1952	Chloropromazin	Anti-psychotic (neuroleptic)
1956	Tolbutamide	Oral anti-diabetic
1960	Chlordiazepoxide	Tranquilizer
1962	Verapamil	Anti-hypertensive (calcium channel blocker)
1963	Propranolol	Beta-blocker (used for hypertension, anxiety and panic)
1964	Furosemide	Diuretics (congestive heart failure and edema)
1971	L-DOPA	Neurotransmitter (Parkinson's disease)
1975	Nifedipine	Calcium channel blocker (anti-hypertensive)
1976	Cimetidine	H ₂ -blocker (peptic ulcer)
1981	Captopril	Angiotensin-converting enzyme (ACE)-blocker (anti-hypertensive)
1981	Ranitidin	H ₂ -blocker (peptic ulcer)
1983	Cyclosporin A	Immunosuppressive
1984	Enalapril	ACE-blocker (anti-hypertensive)
1985	Mefloquin	Anti-malarial
1986	Fluoxetine	Anti-dipressant (serotonin reuptake inhibitor)
1987	Artemisinin	Anti-malarial
1987	Lovastatin	Hypolipidemic (prevention of cardiovascular disease)
1988	Omeprazole	Proton pump inhibitor (Anti-ulcer)
1990	Ondansetron	5-HT ₃ -Blocker (anti-emetic)
1991	Sumatriptan	Anti-migraine headaches
1993	Risperidone	Anti-psychotic (Schizophrenia)

The list of drugs in the table was adopted from Böhm et al, 2002 with modification (Böhm et al, 2002).

Pharmaceutical Industry

Development of Drug Manufacturing

In 1668, Merck, a German company, was presumably the first visitor to Darmstadt. By producing and selling alkaloids for auction, Heinrich Emanuel Merck initiated a shift in 1827 toward a technological and regulated business (Merck Group History, 2012). The origins of GlaxoSmithKline date back to 1715; nevertheless, Beecham didn't improve and complicate the mechanical outcome of cures until the 19th century, when he invented a remedy in 1842 and opened the first store in history dedicated to bearing-only cures in 1859 (GSK History, 2012).

Two German immigrants founded Pfizer in the United States in 1849, initially producing high-quality bullets for the armaments industry. They expanded quickly during the American Civil War as the need for analgesics and painkillers increased (Pfizer History, 2012). Colonel Eli Lilly was a young administrator in the cavalry who worked for Pfizer, supplying the medications needed for the Union war effort. Lilly, a dynamic and multi-talented American billionaire of the 19th century, was a renowned drug researcher. She initiated the drug trade in 1876, was the first to introduce new regulations into the sector, and was the first to focus on research and development in addition to production.

After basic knowledge about the isolation and liberation of synthetic ingredients from coarse pharmaceuticals advanced, the quantity and composition of pharmaceutical workers rapidly changed. It resulted in the creation of manufactured allures in the meantime. The purpose was to intentionally possess pharmacologically pure chemicals that were either manufactured at the workshops, obtained via regular holdings, or obtained from solitude. Operations and medicine manufacture handled both public and private funds, and drug displays expanded quickly. Drug companies that date back thousands of years are still in operation today, and they have a hugely negative financial impact on the nation. A handful of the drug-related activities that helped the early development of modern treatments by introducing a few key medications are listed in Table 2.

Table 2. Chronological Order of Commercialization of Some Important Modern Drugs

Year	Drug substance	Commercial resource	Producer
1826	Morphine (natural compound)	Plant	Merck
1899	Acetyl salicylic acid		
	Aspirin (synthetic analogue)	Plant	Bayer
1941	Penicillin (natural compound)	Microbe	Merck
1964	Cephalothin (semi synthetic)	Microbe	Eli Lilly
1983	Cyclosporin A (natural compound)	Microbe	Sandoz
1987	Artemisinin (natural compound)	Plant	Baiyushan
1987	Lovastatin (natural compound)	Microbe	Merck
1988	Simvastatin (semi-synthetic)	Microbe	Merck
1989	Pravastatin (semi-synthetic)	Microbe	Snakyo/BMS
1990	Acarbose (natural compound)	Microbe	Bayer
1993	Paclitaxel (natural compound)	Plant	BMS
1993	FK506 (natural compound)	Microbe	Fujisawa
1994	Fluvastatin (synthetic analogue)	Microbe	Sandoz
1995	Docetaxel (semi-synthetic)	Plant	Rhone PR
1996	Topotecan (semi-synthetic)	Plant	SKB,Pharmacia-Upjohn
1996	Miglitol (synthetic analogue)	Plant, Microbes	Bayer

This table is taken from Grabley & Thiericke, 1999 with modification.

Economic Impact of Drug Manufacturing

Today, the income accumulation from big drug manufacturing is more generous than that of many narrow and poor countries with their governments. The top ten Drug businesses based on income accumulation Table 3 (Roth et al., 2010) contains their list. The horrifying financials of drug labor have affected efforts to advance human physical research and medicine. Meanwhile, it is also responsible for widening the wealth disparity that created a society fraught with uncertainty and unease. These powerful drug companies have the financial wherewithal and political clout to take on the entire nation by upending its social order. Of the total profit made by the top 50 drug parties, 59.40% went to the top 10 drug enterprises. The top 20 drug workers account for 81.53% of the top 50 drug guests' total earnings; as a result, the world's drug marketplaces are dominated by a plentiful supply.

Table 3. Top Twenty Pharmaceutical Companies Based on 2010 Revenues (in Million USD)

Pharmaceutical Industry		Revenue (Millions USD)
1.	Pfizer	58,523
2.	Novartis	44,420
3.	Merck & Co.	39,811
4.	Sanofi-Aventis	37,403
5.	Glaxo-SmithKline	36,156
6.	AstraZeneca	32,515
7.	Johnson & Johnson	22,396
8.	Eli Lilly & Co	21,685
9.	Abbott Laboratories	19,894
10.	Bristol-Myers Squibb	19,484
11.	Teva	16,121
12.	Takeda Pharma	14,829
13.	Bayer Schering	14,485
14.	Boehringer_Ingelheim	12,883
15.	Astellas	11,161
16.	Daiichi-Sankyo	10,794
17.	Eisai	8,542
18.	Otsuka Pharmaceutical	8,440
19.	Gilead Sciences	7,390
20.	Mylan	5,404

The Most Industrialized Drugs

Every year, old medications are reintroduced and replaced with new, more powerful ones that are obtained through a death stock exchange. Drug energies are fiercely competing with one another to increase production profits. Furthermore, a few medications ought to be taken off the market because they do not identify side effects. As a result, it is challenging to distinguish yourself as the best selling medication of this time. Table 4 displays the upper class of the top ten auction pharmaceuticals based on income accumulation (top ten auction drugs, 2011). One medicine at auction brings in a lot more money than the annual budget of a small, weak nation.

Table 4. Top Ten Pharmaceutical Products World Wide Based on Yearly Revenue Collection

Drug name	Treatment for	Produced by	Sale (billions)
1. Lipitor (Atorvastatin)	Statin i.e., a cholesterol-lowering drug. Lowers LDL cholesterol and triglyceride levels	Pfizer	13.5
2. Plavix (Clopidogrel)	Inhibits blood clots in arteries such as coronary, carotid and peripheral arteries of the limbs and prevents ischemia and thrombosis	Bristol-Myers Squibb & Sanofi-Aventis	7.3
3. Nexium (Esomeprazole)	A proton pump inhibitor (H ⁺ /K ⁺ -ATPase enzyme) which is used in the treatment of dyspepsia, peptic ulcer disease, gastro esophageal reflux disease.	AstraZeneca	7.27
4. Seretide/ Advair (Fluticasone+ salmeterol) -	It is a bronchodilator which relaxes the muscles in the walls of the small air passages in the lungs.	GlaxoSmith Kline	7.1
5. Enbrel (Etanercept)	A tumor necrosis factor (TNF)-blocker, is widely used in immune diseases (rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis) and reduce inflammation.	Amgen and Wyeth	5.3
6. Zyprexa (Olanzapine)	An atypical antipsychotic used in the treatment of schizophrenia, depressive episodes associated with bipolar disorder, acute manic episodes and maintenance treatment in bipolar disorder.	Eli Lilly	5.3
7. Risperdal (Risperidone)	Risperidone is an antipsychotic used to treat schizophrenia including adolescent schizophrenia, the mixed and manic states associated with bipolar disorder, and irritability in children with autism.	Janssen-Cilag	4.9
8. Seroquel (Quetiapine)	An antipsychotic used in the management of schizophrenia and bipolar I disorder, including insomnia and anxiety disorders.	AstraZeneca	4.6
9. Singulair (Montelukast sodium)	A leukotriene receptor antagonist used in the treatment of asthma and to relieve symptoms of seasonal allergies.	Merck & Co., Inc	4.5
10. Aranesp (Darbepoetin alfa)	A synthetic form of erythropoietin which stimulates erythropoiesis to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.	Amgen	4.4

Revenue collection is expressed as in 1 year (billion).

Global Drug Display

With a compound annual tumor rate of 9.3% between 1999 and 2009, the global pharmaceutical market grew to \$808 billion in 2009. A number of blockbuster patents that expired in 2008 and 2009, as well as cost restraints in the US and major European markets, contributed to the year-over-year decline in tumors in all-encompassing medication displays, which reached 4.6% in 2009. In addition to the creation of about 125 pharmacological substances, there have been \$1 billion in global transactions. In 2009, the primary therapeutic areas covered by all-inclusive medication transactions were the central nervous system (CNS), with a 15.8% market share, and the cardiovascular system, with a 14.5% share. Between 2009 and 2014, the amount of money spent on CNS drug ads will drop to \$118.5 billion. Together, the Big Five – Germany, France, Italy, Spain, and the UK – justified more than more than 60% of all drug companies in Europe. By 2012, the global drug display is expected to generate over a trillion dollars in revenue, according to "Global Pharmaceutical Market Forecast to 2012."

One such these is the cancers' transition from developed to emerging markets. increasing patient efforts focused on biotech-related medications, a decline in the number of new drug approvals, and significant advancements in the dominance of generics (Global Display, 2012).

Role of Pharmaceutical Technology

Dosage Form of Modern Medicine

Drugs are typically not produced as pure synthetic materials that are intended to be developed as treatments. The medication is given on human corpses along with the proper vitamins or excipients. Preservatives are mostly used to prepare a distinct portion of a drug or other consumable forms and to find and obtain the greatest healing agent. Donated dosage forms are being used to support the creation of innovative pharmaceutical production processes. Table 5 displays the relevant principal components of medications or other consumable forms (York, 2007).

Table 5. Currently Available Some Important Doses Form of the Modern Medicines

Route of administration	Dosage forms
Oral	Tablets, capsules, powder, granules, emulsion, suspension, syrup, solution
Topical	Cream, pastes, lotions, ointments, gels, solution, transdermal patches, topical aerosol
Rectal	Ointment, Suppositories, creams, powder, solutions
Parenteral	Injections (solution, suspension emulsion), implant
Inhalation	Aerosols, spray, gases
Nasal	Solution, inhalation, spray
Eye	Solution, ointment, cream
Ear	Solution, suspension, ointment, creams

When medications were first being developed, the majority of drug-inclined people were given pharmaceuticals in powder form, and management was communicated. The killing of the abundance is disturbing. The first powdered sleep aid was projected onto the tablet. This offers the pharmaceutical industry a new administration. Patient contracts are selected today, to a greater extent, and the patient's interest is authorized by a choice of verbalization. To increase acquiescence, the flavor was consumed with the medication. Because the drug compound in birth control pills and capsules forms a pleasant and gradual break-up to transport the medication system to the target sites, the drug compound is polluted. Similar drugs provide for the option of being administered via various channels to treat various curative products. For model drug items administered via IV When medications were first being developed, the majority of drug-inclined people were given pharmaceuticals in powder form, and management was communicated. The killing of the abundance is disturbing. The first powdered sleep aid was projected onto the tablet. This offers the pharmaceutical industry a new administration. Patient contracts are selected today, to a greater extent, and the patient's interest is authorized by a choice of verbalization. To increase acquiescence, the flavor was consumed with the medication. Because the drug compound in birth control pills and capsules forms

a pleasant and gradual break-up to transport the medication system to the target sites, the drug compound is polluted. Similar drugs provide for the option of being administered via various channels to treat various curative products. For model drug items administered via IV.




Figure 4. Schematic Diagram Showing Major Routes of Administration in the Human Body and Drug Metabolism

Drug Target

Drug expression is typically carried out through unique pathways into the human population. In order to obtain the therapeutic benefit of the medication, all pharmacological characteristics must be disclosed. Most modern pharmaceuticals have clearly defined drug operation devices; otherwise, they wouldn't be qualified as experts. From the time of administration till the time of withdrawal, the support and efforts of the drugs are fully taken into consideration. Drugs are intentionally designed to act on a specific receptor or enzyme in order for the drug to be accepted. Even with the growing body of knowledge regarding deoxyribonucleic acid logic and comprehension, almost 50% of the medication's efficacies are directed toward the receptor on the containers. The medications either directly bind or activate specific proteins to bind to the receptor fragment, causing the microscopic exercise within the containers to cascade and heal the illness. Certain pathologic settings function by projecting something that stimulates activity and producing overly dramatic or decreased effects. Consequently, medications aim or steer toward a specific objective, which encourages activity endeavor. Almost all tertiary medications available today are designed to target enzymes. A few large.

Figure 5 provides proof of the new medications' operational marks (drews, 2000). knowledge of how drugs bind to ion channels, basic receptors, and dna is almost nonexistent. however, it is appropriate to raise going forward




Figure 5. Biochemical Classes of Drug Targets of Current Therapies

Drug Discovery

The drug-finding project presents a great information, workforce, and service challenge. If all the steps are beneficial based on the knowledge we currently have, it takes till step 14 to make one favorable cure. It might cost a total of 800 tons of US dollars in a 24-hour period. a rough description of the medication. Figure 6 presents a finding plan. A new treatment is hardly ever marketed, even after location or time detail reasoning of almost 100,000 narrow fragments in primary investigation, according to the current flow. Even with enormous work abilities, there are still a lot of medication candidates that are rejected in order to become new therapeutic agents (NDAs). A number of factors improve the efficacy of medications. Not quite, the majority of the medication In both artificial and animal trials, candidates exhibit strong pharmacological properties and turn all interpretations over to humans. The main reason for this is the difficulty of conducting a harsh examination of the pharmacokinetic properties. Table 6 provides a broad flow of drop rate with the drug finding.

Table 6. Failure Rate (%) of Drug Development Process at Different Stages

Failure rate	Percentage
Poor pharmacokinetic properties in human	39
Clinical efficacy	29
Toxicity and adverse effects	21
Commercial limitations	6




Figure. 6. Schematic Diagram of Drug Discovery Strategy

Preclinical Strategy of Drug Discovery

Following a neutral trial, over 70–80% of the entire budget and two years of the total age are spent on drug discovery initiatives. Thus, enhance The preclinical approach ought to be robust, proactive, and rational. Figure 7 probably provides an explanation of the preclinical method's outline.

Evaluation for Bioavailability

Apart from the progress that has been made, the majority of pharmaceuticals are taken orally, and certain drugs are consumed in part or in another consumable form. If a medicine doesn't reach the allure mark station in the frame at the right concentration for the right amount of time, it won't be able to exert its beneficial allure-healing effects. The patient's ability to acquire therapeutic benefit through swallowing a synthetic substance in a capsule that is pharmacologically active, or through any other method, is not satisfied. There are a few other factors to take into account:

In the stomach, the pill might not be splintered, and the drug power may not be made public from the portion of the drug or other consumable form the drug cannot be soluble in the gastrointestinal fluids. If the drug is not dissolved, it will usually not be captivated and will not, within financial means, reach the intend to pass through the epithelial membranes of the gastrointestinal area. Some drugs chemically or enzymatically humiliate the stomach or power the stomach sensitivity. In a few cases, the drug dissolves very fast and is absorbed very fast by the gastrointestinal area, still extreme skin concentration peak, and fast removal, specific drug types have short events of operation so drugs have to be captured very frequently and superior to powerful vacillations in red body fluid aggregation. Some drugs can not be delivered for one spoken route as they are metabolized in the entrails and/or liver, before every strong fluctuations in the aggregation of red blood cells. Certain medications cannot be administered via a single oral route since they must first be processed in the liver or intestines. arriving at the fundamental distribution. Some drugs may have powerful aftereffects that can prohibit an effective situation.

Drugs executed To get to a flowing order, one must get over the stomach barrier via the verbal route. The finest possibility is therefore determined by the

medications that are unquestionably absorbed in the gastrointestinal tract along with intense transportation and residues resistant throughout circulation in a different fabric, especially in the liver and kidneys. Generally speaking, a drug's bioavailability is determined by its synthetic nature. One microscopic breadth and hydrogen sticking capacity are the main indicators that can be used to estimate the bioavailability of the medications (Lipinsky Rule of 5).

The medicinal essence may be top-secret into four groups according to its permeability and solubility (Figure 8). Class I medicines (those with exceptional permeability and solubility) will almost certainly have minimal expression and a high bioavailability. It is exceedingly difficult to attain sufficient bioavailability in the case of Class IV medications (lower permeability and solubility). However, increasing solubility or permeability may strengthen the bioavailability and better expression of Class II or Class III medications.

For those drug nominees bearing depressed solubility or depressed permeability, apiece natural building qualification or use of supplements The bioavailability may be raised. A diagram or graph blueprint To improve bioavailability, we must admit defeat (Figure 9).

Multifunctional Drug Nano-Carriers Drug Delivery

The process of finding new drugs is costly and time-consuming. Furthermore, there is no guarantee that the bidder that wins will ultimately deliver the goods. Consequently, more beneficial therapeutic outcomes will result from study on drug incidents, particularly with regard to the transmittal scheme used to enhance bioavailability. The development of novel drug-transfer technologies also increased the benefits of already-available medications. The nano-warship as the transfer structure is briefly discussed in the current book. Drugs that are potent pharmacologically but cannot be sufficiently absorbed due to toxicity (reaction) or reduced efficacy due to decreased bioavailability are the main targets of nano-shipper drug transmission. Drugs that are less soluble or absorbent generally cannot assemble into the optimal form within the intrinsic distribution. Consequently, These pharmacological types are readily incorporated into lipid nanoparticles in the form of micelles or liposomes. The lipid fragment cluster functions as a nano-one that carries or transmits things, and the drug fragment may be supplied to the focus section because of the drug's encapsulation inside the lipid particle cluster, which determined the tangible features of the drug fragments regulated apiece lipid cluster atom. It is definitely possible to solubilize and puncture a nano-piece of lipid epitomized with medication particles into the container.

Numerous proven medications already exist in nano-one who carries or transmits something formulations. Liposomal expression of amphotericin B is a superb example of nano-warship transfer. With its broad spectrum of action, amphotericin B is the medication of choice for persistently troubling fungal infections, such as aspergillosis, dispersed candidiasis, and protozoal infection involving the internal organs (visceral leishmaniasis). But its application is shamed by mixed antagonistic aftereffects.

But because of nano-a ship that carries airplanes transmittal liposomal expression tree crops such as AmBisome (a limited unilamellar liposomes

expression accompanying the content of 80 nm, composed of hydrogenated soy phosphatidylcholine, cholesterol, destroy phosphatidyl glycerol and amphotericin B in a 2:1:0.8:0.4 something that chops percentage accompanying α -tocopherol), Abelecet (calm of amphotericin B, dimyristoyl phosphatidylcholine and dimyristoyl phosphatidyl glycerol in a 1:1 drug-to-lipid bony object in mouth percentage accompanying sizes be honest to 1.6-11 μm) and Amphotec (containing amphotericin B in a complex accompanying cholesteryl sulfate at a something that chops ration (1:1) accompanying the piece size of 100-140 nm) are commercialized. Lipid-located nano-ones that carry or transmit something formulations are expected superior in clinical productiveness. Based on the lipid type and material condition, the height of pieces, and the nature of the pieces may be devised. In addition, individual or more desired ligands can be introduced to drug-encased nano-atoms that admit the drug molecule expected brought into the focus sites in a reserved manner. The supplementary ligands may be monoclonal microscopic organisms (binds to a particular site), polyethylene glycan (remnants more interminable be present at distribution), binding with weighty alloy (admits to trace the piece), cell stinging peptide (admits the piece to pierce into the cells), DNA binding (admits the DNA expected brought) and attractive nano-carrier (to trace the pieces) (Figure 10). These individual or more ligands may be included in the same atoms so multi-functions of nano-aircraft carriers may be achieved in addition to the transfer of the drugs. Already The first era of multifunctional nano warships is growing. For example, the nano-one who carries or transmits something type (B+C) bearing immuno-specific and PEG ligands can bear the drug fragment to the immuno-specific containers, the ligand binds and transfers the drugs and PEG admits the nano-warship to wait longer hours in the intrinsic distribution (Figure 11).

The future cure will be nanoparticles full of various ligands that will be smart to bear the drug particles to a particular target container accompanying monoclonal antitoxin and penetrate the container sheet and necessary drug can surely be brought outside meddling accompanying the flowing arrangement and different tissues or biomolecules (Figure 12). Such smart drug Childbirth will reduce the aftereffects and enhance drug productivity. This will be the support of 'Intelligent Therapeutics' for future drug formulation.

METHODOLOGY

Study Design: Describe that this is a randomized, reserved trial (RCT) including victims with hypertension. **Participants:** Explain the addition and forbiddance tests for partners. Include analyses on the sample intensity, headcount, and randomization process. **Intervention:** Detail by what method Drug X was executed, containing a portion of drug or other consumable, commonality, and event. **Control Group:** Explain the control group setup and, to a degree, the use of a fake pill or alternative situation.

Data Collection: Describe using what ancestry pressure calculations were captured, in addition to some additional appropriate dossier composed.

Data Analysis: Explain the mathematical procedures secondhand for dossier reasoning, containing some tests for importance.

RESULTS

Present the Key Judgments of the Study

Use tables and figures to display dossiers containing changes in ancestry pressure calculations over time. Include appropriate mathematical studies in the way that p-principles and assurance intervals State whether the results were statistically important.

DISCUSSION

Interpret the results in light of the circumstances of the research question. Discuss whether Drug X was direct in threatening ancestry pressure compared to the control group. Address some restraints of the study, to a degree, potential biases, or narrow sample capacity. Suggest suggestions for the judgments for the hypertension situation and pharmacology. Offer approvals for further research in the way that fact-finding enduring belongings or potential aftereffects of Drug X Concludes by compiling the key takeaways from the study.

Remember that the content and makeup of a paper stating beliefs can change contingent upon the distinguishing research matter, the chronicle's necessities, and the wisdom of the study. This is an abstract model to illustrate the common layout of a long student essay on new cures and pharmaceuticals. Researchers follow the directions of their distinguishing mark chronicle and supply more particularized facts that establish their study's traits.

CONCLUSIONS AND RECOMMENDATIONS

Happy history, more athletic life, and long-awaited growth have existed as the aim of human life knowledge. Modern cure, not completely in part, donated to benevolence to enhance more prosperous and more polished. In fact, in the quest for a more productive cure for more athletic and longer lives, it influenced the development of fundamental allure and any branch of natural science. The traditional land-located human demo graphical association revolutionized Industrialization and pharmaceutical enterprises have an excellent duty for the globalization of the globe. Moreover, new cure discoveries and incidents are not only financed for more athletic and more interminable life but more heartened to succeed in the development of modern science and Technology.

ACKNOWLEDGMENT

The completion of this research project would not have been possible without the contributions and support of many individuals and organizations. We are deeply grateful to all those who played a role in the success of this project We also thank My Mentor [. Naweed Imam Syed Prof. Department of Cell Biology at the University of Calgary and Dr. Sadaf Ahmed Psychophysiology Lab University of Karachi for their invaluable input and support throughout this research. Their insights and expertise were instrumental in shaping the direction of this project.

REFERENCES

- Belis M. (February 2012). History of Aspirin, handy from: <http://inventors.about.com/study/inventors/blaspirin.htm> (achieved on 25.02.2012)
- Böhm H. J., Klebe G., Kubinyi H. (2002). *Wirkstoffdesign: Der Weg zum Arzneimittel*, Spektrum Akademischer Verlag, ISBN 3-8274-1353-2, Heidelberg, Germany
- Derosne, J. F. (1803). *Memoire sur l'narcotic*, *Annalen. Chim.*, Vol.45, pp. 257-285
- Drews, J. (2000). *Drug Discovery: A Historical Perspective*, *Science*, Vol.287, (17 March 2000), pp. 1960-1964, connected to the internet ISSN 1095-9203
- Gerhardt, C. F. (1853) *Untersuchungen über wüther wasserfrei organischen Säuren*, *Ann. Chem. Pharm.*, Vol.87, pp. 149-179
- Global Market (2012) handy from <http://computer.network.prlog.org/10124036-worldwide-drug-retail-forecast-to-2012.html> (achieve on 25.02.2012)
- Grabley, S. & Thiericke R. (1999). *Drug Discovery from Nature*, Springer-Verlag, ISBN 3-540- 64844-5, Heidelberg, Germany
- GSK History (February 2012). Available from <http://computer.network.gsk.com/about/annals.htm>. (achieved on 25.02.2012)
- McLagan, T. J. (1876) *The Treatment of severe Rheumatism accompanying Salicin*, *Lancet*, Vol. 1, pp. 342-343 & 383-384.
- Merck Group History (February 2012) handy from <http://computer.network.Merck.de/en/guest/experiences/history.html> (achieved on 25.02 2012)
- Newman, D. J. & Cragg G. M. (2002). *Natural Products as Drugs and Leads to Drugs: The Historical Perspective*, In *Natural Product Chemistry for Drug Discovery*, A. D. Buss & M. S. Butler, (Ed.), 3-27, RSC Publishing, ISBN 978-0-85404-193-0, Cambridge, UK
- Nicolaou, K. C. & Montagnon, T. (2008). *Molecules that Changed the World*, Wiley-VCH GmbH & Co.KGAA, ISBN 978-3-527-30983-3, Weinheim, Germany
- Pelletier, P. J. & Caventou, J. B. (1820). *Recherches Chimiques sur les quinquinas*, *Annalen Chimiques Physik*, Vol.15, pp. 289-318
- Pelletier, P. J. & Magendie, F. (1817) *Recherches Chimiques et Physiologique sur l' ipecacuanna*, *Annalen Chimiques Physik*, Vol.4, pp. 172-185
- Pfizer History (February 2012) handy from <http://computer.network.pfizer.com/about/record/history.jsp>, (achieved on 25.02.2012)
- Piria, R. (1839). *Recherches sur la Salicine et les produits qui en' de'rivent*, *C. R. Acad. Sci*, Vol.8, pp. 479-485
- Roth, G. Y., Brookes, K, Lowe, D. B. (2010). *Top 20 Pharma report*, accessible from http://computer.network.contract-pharma.com/issues/2011-07/view_features/the-top-20-drug-associations/ (achieved on 25.02.2012)
- Seguin, M. A. (1814). *Premier Me'moire sur l'narcotic*, *Annalen Chim*, Vol.92, pp. 225-245
- Sertürner, F. (1805). *Auszuge aus briefen an cavern Herausgeber (a) Säure im Opium. (b) Ein deres Schreiben von Ebendenselben. Nachtrag zur*

- Charakteristik der Säure im Opium, *Journal der Pharmazie für Ärzte, Apotheker und Chemisten* von D. J. B. Trommsdorff, Vol.13, pp. 29-30
- Sertürner, F. (1806). Darstellung der reinen Mohnsäure (Opium säure) nebst einer Chemischen Untersuchung des Opium mit vorzüglicher Hinsicht auf einen darin neu entdeckten stoff und wither dahin gehörigen Bemerkungen, *Journal der Pharmazie* jacket Ärzte, Apotheke, Vol.14, pp. 47-93
- Sertürner, F. (1817). Über criminal lawyer for the government Morphinum, eine neue salzfähige Grundlage, und wither Mekonsäure, als Hauptbestandtheile des Opium, *Gilbert's Annalen der Physik*, Vol.25, pp. 56-89
- Top Ten Selling of the World (2011) vacant from http://computer.network.med.india.net/health_statistics/health_facts/top-ten-business_drugs.htm#ixzz1t8ck78Zv (achieve on 25.02.2012)
- Wright C. R. A. (1874) On the Action of Organic Acids and their Anhydrides on the Natural Alkaloids: Part I, *Journal of Chemical Society*, Vol.27, pp. 1031-1042
- York, P. (2007). Design of portion of drug or other consumable form, In: *Aulton's Pharmaceutics: The Design and produce of Medicine*, 3rd Ed, M. E. Aulton, (Ed.), 4-7, Elsevier Limited, ISBN 978-0-443-10108- 3, London, UK